Methods of modulating and identifying agents that modulate intracellular calcium
Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.
1. A method for treating an autoimmune disease or disorder, comprising administering to a subject having the disease or disorder at least one modulator of a polypeptide, wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:4 or to SEQ ID NO:10 or to SEQ ID NO:52.
2. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:4 or 10 or 52.
3. The method of claim 1 , wherein the at least one modulator modulates the level, functioning, molecular interactions and/or activity of the polypeptide.
4. The method of claim 1 wherein the at least one modulator binds to or interacts with the polypeptide.
5. The method of claim 1 wherein the autoimmune disease or disorder is selected from the group consisting of: psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, Alzheimer's disease, amytrophic lateral sclerosis, multiple sclerosis, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, lupus erythematosus, type I diabetes, pulmonary fibrosis, dermatomyositis, thyroiditis, myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, primary biliary cirrhosis, and atopic dermatitis.
6. The method of claim 5 wherein the autoimmune disease or disorder is rheumatoid arthritis.
7. The method of claim 5 wherein the autoimmune disease or disorder is psoriasis.
8. The method of claim 5 wherein the autoimmune disease or disorder is dermatitis.
9. The method of claim 5 wherein the autoimmune disease or disorder is lupus erythematosus.
10. The method of claim 5 wherein the autoimmune disease or disorder is type I diabetes.
11. The method of claim 4 , wherein the at least one modulator is selected from the group consisting of a protein, a peptide, an antibody and an antibody fragment.